Prognostic and Predictive Biomarkers in Hepatocellular Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (10 July 2023) | Viewed by 14069
Special Issue Editors
Interests: abdominal transplantation; liver transplantation; hepatobiliary and pancreatic surgery; minimally invasive surgery; liver cancer; surgical oncology
Interests: abdominal transplantation; liver transplantation; hepatobiliary and pancreatic surgery; minimally invasive surgery; liver cancer; surgical oncology
Interests: abdominal transplantation; liver transplantation; hepatobiliary and pancreatic surgery; minimally invasive surgery; liver cancer; surgical oncology
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the fourth highest cause of cancer-related deaths worldwide. Potentially curative treatments, such as surgery, radiofrequency or liver transplantation are available for selected patients only, while transarterial chemoembolization or systemic agents are the best treatments for intermediate and advanced stage disease. Indeed, over the last decade, immunotherapy has transformed the treatment of HCC, in particular, following the introduction of immune checkpoint inhibitors (ICPIs). The identification of prognostic and predictive biomarkers to define the best treatment for each patient is urgent.
The aim of the special issue is to identify, describe or validate prognostic biomarkers for the diagnosis and survival of HCC based. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: gastroenterology, hepatology, hepatobiliary surgery, transplant surgery, interventional and diagnostic radiology, medical oncology.
We look forward to receiving your contributions.
Prof. Dr. Marco Vivarelli
Prof. Dr. Federico Mocchegiani
Dr. Andrea Benedetti Cacciaguerra
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- early diagnosis
- prognosis
- biological markers
- biomarkers
- prognostic models
- target therapies
- systemic agents